Background/Aims: Contrast medium-induced acute kidney injury (CI-AKI) is an important iatrogenic complication following the injection of iodinated contrast media. The level of serum creatinine (SCr) is the currently accepted ‘gold standard' to diagnose CI-AKI. Cystatin C (CyC) has been detected as a more sensitive marker for renal dysfunction. Both have their limitations. Methods: The role of the preinterventional CyC-SCr ratio for evaluating the risk for CI-AKI and long-term all-cause mortality was retrospectively analyzed in the prospective single-center ‘Dialysis-versus-Diuresis trial'. CI-AKI was defined and staged according to the Acute Kidney Injury Network classification. Results: Three hundred and seventy-three patients were included (average age 67.4 ± 10.2 years, 16.4% women, 29.2% with diabetes mellitus, mean baseline glomerular filtration rate 56.3 ± 20.2 ml/min/1.73 m2 [as estimated by Chronic Kidney Disease Epidemiology Collaboration Serum Creatinine Cystatin C equation], 5.1% ejection fraction <35%). A total of 79 patients (21.2%) developed CI-AKI after elective heart catheterization, and 65 patients (17.4%) died during follow-up. Multivariate analyses by logistic regression confirmed that the preinterventional CyC-SCr ratio is independently associated with CI-AKI (OR 9.423, 95% CI 1.494-59.436, p = 0.017). Also, the Cox regression model found a high significant association between preinterventional CyC-SCr ratio and long-term all-cause mortality (mean follow-up 649 days, hazards ratio 4.096, 95% CI 1.625-10.329, p = 0.003). Conclusion: The preinterventional CyC-SCr ratio is independently associated with CI-AKI and highly significant associated with long-term mortality after heart catheterization.

Keywords:
Contrast medium-induced acute kidney injury, Preinterventional cystatinߝcreatinine ratio, Heart catheterization, All-cause mortality
1.
Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.
2.
Lameire N, Van Biesen W, Vanholder R: The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2006;2:364-377.
3.
McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
4.
Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, Philipp T, Kribben A: Early detection of acute renal failure by serum cystatin C. Kidney Int 2004;66:1115-1122.
5.
Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699-707.
6.
Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, Riesen W, Wüthrich RP: Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 2004;61:98-102.
7.
Delanaye P, Lambermont B, Chapelle JP, Gielen J, Gerard P, Rorive G: Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units. Intensive Care Med 2004;30:980-983.
8.
Peralta CA, Shlipak MG, Judd S, et al: Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011;305:1545-1552.
9.
Inker LA, Schmid CH, Tighiouart H, et al: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-29.
10.
Reinecke H, Fobker M, Wellmann J, Becke B, Fleiter J, Heitmeyer C, Breithardt G, Hense HW, Schaefer RM: A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. Clin Res Cardiol 2007;96:130-139.
11.
Mehta RL, Kellum JA, Shah SV, et al: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
12.
Levey AS, Greene T, Kusek JW, Beck GL; MDRD Study Group: Simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:A0828.
13.
Levey AS, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
14.
Larsson A, Malm J, Grubb A, Hansson LO: Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004;64:25-30.
15.
Inker LA, Schmid CH, Tighiouart H, et al: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-29.
16.
Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019-3041.
17.
Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH: Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993;44:1217-1223.
18.
Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD, Katholi CR, Moses HW, Mishkel GJ, Lucore CL, et al: Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995;195:17-22.
19.
Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L: Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995;6:1451-1458.
20.
Pflueger A, Larson TS, Nath KA, King BF, Gross JM, Knox FG: Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc 2000;75:1275-1283.
21.
Persson PB, Hansell P, Liss P: Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005;68:14-22.
22.
Levey AS, Berg RL, Gassman JJ, Hall PM, Walker WG: Creatinine filtration, secretion and excretion during progressive renal disease. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl 1989;27:S73-S80.
23.
Shemesh O, Golbetz H, Kriss JP, Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830-838.
24.
James GD, Sealey JE, Alderman M, Ljungman S, Mueller FB, Pecker MS, Laragh JH: A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens 1988;1:124-131.
25.
Stevens LA, Lafayette RA, Perrone RD, Levey AS: Laboratory evaluation of kidney function; in Schrier RW (ed): Diseases of the Kidney and Urinary Tract, ed 8. Philadelphia, Lippincott Williams & Wilkins, 2007, pp 299-336.
26.
Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C: Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003;63:1944-1947.
27.
Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933-1953.
28.
Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP: Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312-318.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.